A Single Rising Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150

Trial Profile

A Single Rising Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150

Completed
Phase of Trial: Phase I

Latest Information Update: 05 May 2017

At a glance

  • Drugs MK 8150 (Primary)
  • Indications Hypertension
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 17 May 2016 Time frame of Primary endpoint Number of Participants with Adverse Events (AEs) and Number of Participants who Discontinue due to AEs changed from Approximately 20 weeks to approximately 42 days. And also Time frame of Time-weighted Average Across 24 hours and Mean Time Weighted Average over 12 hours changed to Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16 and 24 hours post dose.
    • 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top